TY - JOUR T1 - Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative JF - BMJ Innovations JO - BMJ Innov DO - 10.1136/bmjinnov-2018-000317 SP - bmjinnov-2018-000317 AU - Katherine Deane AU - Laure Delbecque AU - Oleksandr Gorbenko AU - Anne Marie Hamoir AU - Anton Hoos AU - Begonya Nafria AU - Chi Pakarinen AU - Ify Sargeant AU - Dawn P Richards AU - Soren Eik Skovlund AU - Nicholas Brooke A2 - , Y1 - 2019/03/02 UR - http://innovations.bmj.com/content/early/2019/03/01/bmjinnov-2018-000317.abstract N2 - Introduction Meaningful patient engagement (PE) can enhance medicines’ development. However, the current PE landscape is fragmentary and lacking comprehensive guidance.Methods We systematically searched for PE initiatives (SYNaPsE database/publications). Multistakeholder groups integrated these with their own PE expertise to co-create draft PE Quality Guidance which was evaluated by public consultation. Projects exemplifying good PE practice were identified and assessed against PE Quality Criteria to create a Book of Good Practices (BOGP).Results Seventy-six participants from 51 organisations participated in nine multistakeholder meetings (2016–2018). A shortlist of 20relevant PE initiatives (from 170 screened) were identified. The co-created INVOLVE guidelines provided the main framework for PE Quality Guidance and was enriched with the analysis of the PE initiatives and the PE expertise of stakeholders. Seven key PE Quality Criteria were identified. Public consultation yielded 67 responses from diverse backgrounds. The PE Quality Guidance was agreed to be useful for achieving quality PE in practice, understandable, easy to use, and comprehensive. Overall, eight initiatives from the shortlist and from meeting participants were selected for inclusion in the BOGP based on demonstration of PE Quality Criteria and willingness of initiative owners to collaborate.Discussion The PE Quality Guidance and BOGP are practical resources which will be continually updated in response to user feedback. They are not prescriptive, but rather based on core principles, which can be applied according to the unique needs of each interaction and initiative. Implementation of the guidance will facilitate improved and systematic PE across the medicines’ development lifecycle. ER -